Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Several possible studies

Story checked

GLP-1s 101: What the science says about weight loss, side effects, safety (opens in a new tab)

med.stanford.edu · 2026-06-29

Short answerEvidenceSource

Short answer

Several possible studies

No confirmed study match.

Several papers could fit this story, but none could be confirmed as its source. The claims remain unverified.

16 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Several studies could be the source of this story.

More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.

Open claim evidence
3

Search result

Several studies could fit.

More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.

Source paper

Source layer

The paper behind the story

The source record for this check.

The research anchor for the report.

The literature search

16 candidate papers

Papers surfaced in our search

These papers appeared in the search for the story’s source. None was confirmed as a direct match. Inclusion here does not mean a paper supports or contradicts the story, or that its full text was reviewed.

Show 12 more search results
Then inspect each claim

Evidence layer

Claim by claim

What the story asserts. With no source study, there is nothing to check these against.

Claim 1 of 8Not checkedGLP-1 agonists such as Ozempic/Wegovy (semaglutide) and Zepbound/Mounjaro (tirzepatide) have transformed how medicine approaches obesity, diabetes and some other conditions.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 2 of 8Not checkedThese drugs mimic the GLP-1 hormone, slow gastric emptying, increase insulin release, act on brain satiety centers, and usually make patients eat less.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 3 of 8Not checkedTrials have shown that tirzepatide leads to more weight loss than semaglutide on average, though different patients respond differently to each drug.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 4 of 8Not checkedSemaglutide is FDA-approved to reduce the risk of major cardiovascular events in patients with established cardiovascular disease, and in the SELECT trial it cut the rate of major cardiac events by 20%.View evidenceHide evidence

As stated20%

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 5 of 8Not checkedOn average, semaglutide produces about 15% body weight loss in people without diabetes and tirzepatide about 20%, but roughly 10% to 15% of patients lose close to no weight even at the maximum dose.View evidenceHide evidence

As stated15% and 20% average body weight loss; 10% to 15% minimal responders

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 6 of 8Not checkedThe most common side effects are gastrointestinal, including nausea, vomiting, constipation, diarrhea, acid reflux, and reduced thirst; one clinician said nearly all of her young patients have nausea.View evidenceHide evidence

As stated100% nausea in one clinician's adolescent patients

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 7 of 8Not checkedIf patients stop semaglutide or tirzepatide, most regain weight, and the article cites a 2026 analysis of more than 9,000 patients plus the STEP 1 trial extension as evidence.View evidenceHide evidence

As statednearly 2 pounds a month; two-thirds of lost weight regained after a year

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 8 of 8Not checkedThe clinicians interviewed generally think GLP-1 medications should be taken long term, often for life, because obesity is treated as a chronic disease and stopping usually leads to regain.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Finally, the search trail

Method layer

No single source study was found.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results

Candidate papers, not confirmed sources.

Crossref, PubMed, Europe PMC · 16 candidate papers

Explore all search results